Investigating how HIV affects the development of classic Hodgkin lymphoma
Official title: Understanding the pathogenesis of classic Hodgkin lymphoma in persons living with HIV through conventional and spatial transcriptomics
Funded at Fred Hutchinson Cancer Center · NIH-10954155 · Data updated 2026-11-12
This study is looking at why people with HIV might have a higher chance of developing classic Hodgkin lymphoma, and it aims to understand the differences in their immune system and genes that could lead to this cancer, with the help of patient samples.
Quick facts
| Grant type | R03 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Fred Hutchinson Cancer Center NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project start | August 8, 2024 |
| Project end | July 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $176,000 |
| NIH project number | 1R03CA288191-01A1 |
| Project ID | NIH-10954155 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals living with HIV who are at risk of developing classic Hodgkin lymphoma.
✕Less likely to help
Patients who do not have HIV or those who have already been diagnosed and treated for classic Hodgkin lymphoma may not benefit from this research.
What this research studies
This research explores the increased risk of classic Hodgkin lymphoma (CHL) in individuals living with HIV. It focuses on understanding the unique immune environment and genetic changes in these patients that may contribute to the development of this type of cancer. By utilizing advanced techniques like spatial transcriptomics, the study aims to uncover the underlying mechanisms that differentiate CHL in HIV-positive patients from those in the general population. Patients may be involved in providing samples to help researchers analyze these differences.
Why it matters
Potential benefit: If successful, this research could lead to improved understanding and treatment strategies for classic Hodgkin lymphoma in patients living with HIV.
How similar studies have gone: Previous studies have indicated that understanding the immune microenvironment can significantly impact cancer treatment, suggesting that this approach may yield valuable insights.
Where this research is happening
-
Fred Hutchinson Cancer Center
Seattle, United States Active
Researchers
- Principal investigator: Naresh, Kikkeri — Fred Hutchinson Cancer Center
- Study coordinator: Naresh, Kikkeri
Related research
Other NIH-funded projects on the same topics.
-
Understanding why Black and Hispanic Hodgkin lymphoma patients have worse survival
A patient-centered study to uncover social and care factors that contribute to lower survival among Black and Hispanic people with Hodgkin lymphoma across all ages.
-
Novel combination therapy for non-Hodgkin lymphoma in people and dogs
A new treatment combo using an oncolytic virus and other therapies is being tested to help people with hard-to-treat non-Hodgkin lymphoma, with studies also involving dogs to better understand responses.
-
Trajectories of Neurotoxicity in young Hodgkin lymphoma patients
Aging Hodgkin lymphoma patients who are adolescents or young adults may face long-lasting brain and nerve-related side effects from their cancer treatment, and this study aims to map how those problems develop over time.
-
Combination therapy approach for non-Hodgkin lymphoma (NHL)
A Mayo Clinic team is testing a new combination treatment for non-Hodgkin lymphoma to improve responses in patients and in dogs with similar disease.
-
Multi-antigen T cell therapy for relapsed NHL
A patient-derived T cell therapy called MT-601 targets six tumor-associated antigens to help treat relapsed non-Hodgkin lymphoma after other therapies may have failed.
-
Personalized de‑intensification of therapy for NLP Hodgkin lymphoma
A clinician-scientist at Stanford is developing a patient-centered program to tailor and reduce therapy for nodular lymphocyte-predominant Hodgkin lymphoma using tumor and blood samples.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.